Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Canaccord raised the firm’s price target on Boston Scientific (BSX) to $117 from $101 and keeps a Buy rating on the shares. The firm said they ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

Canaccord Genuity maintained its Buy rating on Boston Scientific (NYSE:BSX) shares and increased the price target to $117 from $101. The adjustment follows the company's robust fourth-quarter earnings ...

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Crunchy mom influencers often speak with an authority that comes not necessarily from scientific rigor but ... strong health freedom component, gained momentum in the 2010s, as pushback over ...

Medtronic is racing against Boston Scientific to expand in one of medtech’s hottest ... Medtronic’s neuromodulation business is gaining new momentum with investments in sensing technology for the ...

The Celtics will need to bring their 'A' game on both ends with the players available if they don't want to extend their ...

Louisville starting guard Chucky Hepburn exits the game with an injury. Boston College guard Chas Kelley III exits the game ...